PeptideCompareCrystagen — EU research guide.
Crystagen (Glu-Asp-Pro) is a synthetic tripeptide bioregulator from the Khavinson series, targeting central nervous system tissue. It is studied for cognitive support and neuroprotection in aging models.
What is Crystagen?
Crystagen is a short tripeptide proposed to have preferential affinity for CNS tissue, interacting with chromatin and modulating gene expression in neurons and glial cells. Like other Khavinson bioregulators it is hypothesised to act as an epigenetic regulator of tissue-specific protein synthesis.
What does the research show?
Preclinical studies from Russian institutions report improved memory consolidation in aged animal models, reduced oxidative damage in neuronal cultures and neuroprotective effects in ischaemia models. Human data is limited to small observational studies in elderly subjects reporting subjective cognitive improvements. No randomised controlled trials in Western peer-reviewed literature.
EU legal status
Not approved in the EU. Available from specialist research vendors as a laboratory compound for CNS research purposes only.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Estimates modelled per compound from its molecular properties (sequence length, cyclisation, oxidation- and deamidation-prone residues, light sensitivity). Indicative only — not lab-measured per batch.
Crystagen across EU suppliers
COA-verified EU vendors · Updated monthly